In a lecture in January 1896 WILHELM CONRAD ROENTGEN demonstrated a new kind of radiation (Xrays), which penetrated human tissue and blackened (or darkened) photographic films. In an early experiment, the X-rays had passed through the hand of his wife before impacting on a photographic film. On this film the shadow of the skeleton inside the fingers and the shadow of a metal ring around one of the fingers were whiter (brighter) and contrasted against the blacker (darker) shadows of the soft tissues of the fingers. The blood vessels in the soft tissues were invisible. Obviously, the skeleton and the metal ring, but not the vessels, attenuated the X-rays more than did the soft tissues.
In a lecture in January 1896 WILHELM CONRAD ROENTGEN demonstrated a new kind of radiation (Xrays), which penetrated human tissue and blackened (or darkened) photographic films. In an early experiment, the X-rays had passed through the hand of his wife before impacting on a photographic film. On this film the shadow of the skeleton inside the fingers and the shadow of a metal ring around one of the fingers were whiter (brighter) and contrasted against the blacker (darker) shadows of the soft tissues of the fingers. The blood vessels in the soft tissues were invisible. Obviously, the skeleton and the metal ring, but not the vessels, attenuated the X-rays more than did the soft tissues.
A few weeks later HASCHEK & LINDENTHAL (15) filled the blood vessels of an amputated hand with a suspension containing a skeletal component (chalk -a calcium compound) and a metallic component (Zinnober -a mercury compound). On roentgen films of the hand the vessels filled with the suspension were visible because they now absorbed X-rays more than did both the skeleton and the soft tissues. The first angiography had been made. The suspension had apparently functioned as a medium producing contrast in the roentgen films between the shadow of the vessels and the shadow of their surroundings. Since this beginning, there has been steady evolution towards the development of less toxic contrast medium compounds, allowing their use in vivo and making them important tools in diagnostic radiology.
In this presentation an object means a structure of diagnostic interest in the body. We define a contrast medium as a substance which creates increased ob--ect contrast, i.e, an increased difference in attenuai;,;.,, ' . of X-rays between an object and its surroundi ;' 0~; ' This task can be performed only on the condi-tion that the contrast medium at some moment achieves different concentrations in the object and in its surroundings.
The theme of this paper is a recently developed contrast medium, Visipaque (Nycomed). It is presently available for intravascular use as plasma-isotonic aqueous solutions of the nonionic (neutral) iodine compound iodixanol. These water-based solutions are enriched with sodium and calcium salts.
I will try to give Visipaque a place in the ongoing evolution towards the never achievable goal -development of the ideal water-soluble contrast medium for angiography and for the extracellular space.
The ideal contrast medium
In the ideal world a contrast medium should have maximal efficacy (maximal attenuation of X-rays) and maximal safety (produce no adverse effects).
In the real world maximal efficacy means that the medium should produce maximal object contrast in the human body, so that the X-ray detectors (roentgen films, intensifying screens, detectors of CT machines, etc.) can (from the X-rays coming out from the body) measure a difference in attenuation between that object and its surroundings and thereby produce a final image for the human eye with maximal image contrast between the images of the object and its surroundings.
In the real world maximal safety means that the medium should have minimal toxic or adverse effects on body functions and patient comfort and should also have minimal viscosity, to allow injection through needles or catheters as thin as possible in order to minimize the risk of damage to tissues from needles and catheters.
When looking for qualities of Visipaque that represent steps towards (and also qualities representing steps away from) an ideal contrast medium, it may help to first review some basics about the improved detection of structures in the body with X-rays when contrast media are used and then review the historical development of the media. Such a review should not only deal with efforts to improve efficacy (attenuation of X-rays) and safety (i.e., toxicity) of the contrast-producing compounds per se, but also deal with efforts to minimize adverse effects due to osmolality, electrolyte composition and viscosity of aqueous solutions of those compounds.
Detection of objects (structures of diagnostic interest)
inside the body with X-rays
An object in the above context may be a complete organ or a normal or abnormal anatomic detail or a disease process inside that organ. Some examples of such objects are: the whole liver or a lobe of the liver, a kidney, the fat tissue surrounding a kidney, a normal blood vessel or an aneurysm, stenosis, arteriosclerotic ulceration or dissection in the vessel wall, a brain region with a leaking blood-brain barrier, a primary tumor, a tumor metastasis, a necrosis inside a tumor, an abscess, the wall of an abscess, a bone with normal skeletal structure, a fracture in a bone, etc. Some statements can be made about the ability of X-ray techniques to detect objects in the body:
1. an object can be detected only on the condition that there exists an object contrast, i.e., a measurable difference in the attenuation of the X-rays between that object and its surroundings;
2. the larger the object contrast, i.e., the larger the difference in attenuation between the object and its surroundings, the smaller that object can be without coming below the threshold of detectability;
3. X-ray contrast media are used to create or increase object contrast and there are thus structures in the body which can be detected with X-rays only on the condition that a contrast medium is used.
From statements 2 and 3, it follows that with a higher difference in contrast medium concentration between an object and its surroundings, the smaller that object can be and still come above the threshold of detectability with X-rays. In arteriography with the injection of a contrast medium bolus into an artery, this explains the well known clinical experience familiar to the angiographer that with a higher iodine concentration in a contrast medium solution (and thereby also inside an arteriographic contrast medium bolus), smaller structures are detected in the wall of that artery. This is due to the increased difference in contrast medium concentration between the endothelium (containing virtually no contrast medium) and the lumen of the artery (containing the contrast medium bolus). In the individual patient the safer detection of small objects may change the diagnosis (or details of the diagnosis) and thereby result in a change in therapy (or details of the therapy).
The production of X-rays at the price of heating the focus An X-ray tube is a vacuum tube in which electrons from a cathode are accelerated under the influence of an electric field (20-150 kV) before they strike the metal at the focus of the anode. More than 99% of the kinetic energy of the electrons is transformed into thermal energy in the focus and less than 1% is transformed to X-ray photons inside the focus. This imposes restrictions on the amount of radiation that can be produced per unit oftime from an X-ray tube.
In order not to melt the metal in the focus and destroy the X-ray tube, one is often forced to use longer exposure times than ideal ones, with the associated risk of motion-derived blurring in the images, or one is forced to use higher kV setting (higher photon energies), which results in less good object contrast (see below).
The radiation out ofan X-ray tube contains a spectrum ofphoton energies
In CT or in imaging of the chest, an electric field of 150 kV may be used to accelerate the electrons in the X-ray tube so that they have kinetic energy of around 150 keY when striking the focal area. These energy-rich electrons interact randomly with the atoms in the focus. Only a few electrons transform all their kinetic energy to X-ray photons, which then get the maximal photon energy of 150 keV. The majority of the electrons transform most of their kinetic energy to thermal energy in the focus and only a minor and varying fraction of their energy into X-ray photons. Therefore, out of the focus of the X-ray tube comes a stream of radiation with photons displaying (representing) a spectrum of photon energies; a few photons have the maximal r2~2 000 720
The data are from reference 42 and contain interpolation of data at photon energy levels (keV) 35 , 70 and 90. The vertical arrows show the K-edges energy of 150 keY but the vast majority have a much lower energy. The atoms of the body, or of the contrast medium, attenuate X-ray photons of low energy much more efficiently than X-ray photons of high energy (with local exceptions at the K-edges) ( Table 1) . Therefore, X-ray photons of very low energy (for instance below 20 keY) have very small statistical chances of being useful (i.e. to pass through the body and then reach a detector of Xrays) but they maintain their statistical chances of interacting with molecules of the body and causing radiation damage by breaking chemical bonds and! or producing free radicals. These low-energy photons are eliminated by, for instance, the use of aluminium filters. Large numbers of photons radiate out of an X-ray tube for CT or chest imaging and represent a spectrum of photon energies of between 150 keV and 20 keY.
For urography, a lower tension may be applied to the X-ray tube (70 kV) than for imaging of the chest, producing a spectrum of photon energies of between 70 keV and 20 keV to get a better fit between the applied photon energies and the ability of the iodine atoms in urographic contrast media to attenuate photons of different energies (Table 1) . Iodine atoms attenuate a spectrum of radiation of lower photon energies more efficiently than a spectrum of higher photon energies. The spectrum of photon energies streaming out of an X-ray tube is often regarded as being composed of a large number of individual beams of different photon energies. Each single "beam" is then regarded as monochromatic, i.e., as containing only 1 level of photon energy. Examples of the total attenuation of a number of monochromatic X-ray beams by different atomic species are given in Table  1 . At the voltages applied to the X-ray tubes in diagnostic radiology (20-150 kV), the total attenuation of the X-ray photons by the atomic electrons inside the human body is due to the sum of 3 effects: these are photoelectric absorption, incoherent (Compton) scattering and coherent (Rayleigh) scattering.
A monochromatic X-ray beam containing a narrow range of photon energies will be discussed in the following: The total attenuation of such a beam by an atom is measured in the unit barns per atom (I barn=1O-28 rrr') and is also described as the individual atomic cross-section of the sum of the 3 absorption and scattering mechanisms mentioned above. Table I shows the total attenuation of such monochromatic beams by some individual atoms. One barn may be regarded as a small surface (a crosssection) with approximately the same cross-section as the nucleus of the hydrogen atom (10-28 rrr'), The number of barns per atom represents the area of a small imaginary shield that the atom holds against this monochromatic radiation, attenuating it by absorption and scattering. The larger the area of this imaginary shield, the larger the statistical chance that the atom will interact with the radiation (at the photon energy of current interest) and attenuate it. However, since out of an X-ray tube comes a spectrum of photon energies, one has to add (integrate) the barns per atom values obtained for all the photon energies of this spectrum in order to determine the attenuation of the total spectrum of radiation by a given atomic species. Table 1 is a compilation of data from reference 42 and demonstrates 2 main rules:
1. When going from the top to the bottom of Table 1 , i.e., exposing atoms of increasing atomic mass to a monochromatic beam of constant photon energy, you will find that at all photon energies the total attenuation of X-rays (expressed as total barns per atom) increases with increasing mass of the atoms (with local exceptions at the K-edges as described below).
2. When going from left to right in Table 1 , i.e., exposing an atomic species to monochromatic Xray beams of increasing photon energy, you will find that for all atomic species the total attenuation ofX: rays decreases with increasing photon energy of the X-rays (with local exceptions at the K-edges).
The K-edge of an atom represents a border value for the X-ray photon energy -above the K-edge the X-ray photons have enough energy to eject electrons from the K-shell, while at energy levels below the K-edge value, the photons cannot eject those electrons. Therefore, at fairly narrow levels of photon energies, just above the K-edge of an atom, there are exceptions from the main rules above. In such instances the atom:
1. becomes a better attenuator than at the lower photon energy below the K-edge and 2. becomes a better attenuator of radiation than some of its neighbors in the periodic system with a higher atomic mass (for instance, at a photon energy 70 keV tungsten becomes a better attenuator than lead).
Object contrast is due to differences in the number of atoms and/or species of atoms per unit volume between an object and its surroundings
It follows from common sense (factor 1 below) and
from Table 1 (factor 2 below) that 1. with an increasing number of atoms inside a volume unit of a structure in the body, there will be A) a greater density (mass per volume) of that struc-ture; and B) a larger attenuation of radiation from that volume unit (a larger number of barns per volume); 2. the larger the average atomic mass of the atoms in that volume unit, the larger the degree of attenuation from that volume (the larger the number of barns of that volume) will be.
In short: A difference in attenuation between a structure in the body and its surroundings may be due to 1. a difference in density (mass per volume); andl or 2. a difference in atomic composition. An example of the effect of a difference in density: On an X-ray film of the chest you may see branches of the pulmonary arteries and veins contrasting against the pulmonary parenchyma due to a higher attenuation of X-rays by the pulmonary vessels than by the pulmonary parenchyma. This difference in attenuation is mainly due to differences in density. The attenuation of radiation by the vessels is due to the vessel wall and the blood inside the vessels, consisting mainly of water and various organic compounds, i.e., mainly a mixture of hydrogen, carbon, nitrogen and oxygen atoms, and with a density of about 1 g/ml vessel and blood.
The pulmonary parenchyma is mixed with connective tissue, small blood vessels, walls of small bronchi and walls of alveola, all of which consist of hydrogen, carbon, nitrogen and oxygen atoms and have a density of about 1 g/ml tissue. However, the pulmonary parenchyma also contains air (a gas comprising mainly nitrogen and oxygen) with a density 1000 times lower, around 1 mg/ml air, so that the actual density of the air-filled pulmonary parenchyma (depending on degree of local emphysema) may be 0.3 g/ml. It is the difference in density (1 g/ml versus 0.3 g/ml) that gives rise to the object contrast between the large pulmonary vessels and the pulmonary parenchyma.
Examples of differences in atomic composition: When a catheter is placed in the left coronary artery and the blood is exchanged for a contrast medium solution containing 300 to 350 mg IIml, the contrast medium-filled vessel lumen has a density of around 1.3 g/ml while the walls of the vessels have a density of around 1 g/ml, It is mainly the high iodine concentration, which gives the vessel lumen (depending on the photon energy of the radiation) a double to 30 times higher attenuation capacity per unit volume (expressed as barns/ml) than the vessel wall, which is composed of mainly hydrogen, carbon, nitrogen and oxygen atoms.
Both experience from phantom studies and the clinic show that the higher the iodine concentration inside a vessel lumen, the smaller the pathological processes in the vessel wall (e.g., arteriosclerosis, arteritis or micro-aneurysms) that can be be detected. Moreover, collateral vessels of a smaller diameter can be detected when the iodine concentration in them increases.
To optimize object contrast -choice of photon energy (kV of X-ray tube)
It can be seen from Table 1 that at low photon energies (20-30 keV), the total attenuation of radiation by different atomic species is much larger than at high photon energies (100-150 keY). Furthermore, at the low photon energies the differences in attenuation between different atomic species are also much larger than at high photon energies. At low photon energies (soft radiation) you get higher object contrast and if this high object contrast also gives a high image contrast, you have produced a hard image. (Soft radiation gives hard images.) To get high image contrast (and thereby a lot of information from the image) one should, therefore, use soft radiation, i.e., low photon energy. But low photon energy means that most photons are absorbed inside the body and few photons have a statistical chance of passing through the body and finally hitting the X-ray detector. At low photon energies you must, therefore, send a larger number of photons into the body (use a larger radiation dose) to get enough photons through the body to the detector. The choice of photon energy (or X-ray tube tension) therefore becomes a compromise. One aims at low photon energy, (i.e., low kV) over the X-ray tube to get high object contrast but high photon energy (high tube tension) to minimize the radiation dose. Therefore, for thinner objects (small children and thin extremities) lower photon energies (allowing good object contrast) are used while for thicker objects (thicker extremities or adults with thick abdominal walls) higher photon energies are used to decrease the radiation dose (with the penalty of inferior object contrast). Thus, the dimensions of the body subjected to X-ray examination may force the choice of a higher kV, i.e., higher photon energy, than is desirable with regard to achieving good object contrast.
The choice of ideal photon energy with regard to ideal object contrast may also be compromised due to movement of the object. To get sharp X-ray images of rapidly moving objects, the time of exposure (time of radiation) must be short, for instance in the order of a few ms. Examples of such objects 'Ire small arteriosclerotic plaques, stenotic (narrow) , 'n segments in a coronary artery or a pathological process on a cardiac valve leaflet, all of which are rapidly moved by the pumping heart. Thus, the desire for a short exposure time, the need of a high enough number of photons to penetrate a thick body and reach an X-ray detector, the low efficacy of Xray tubes (less than 1% of the energy applied emerges as X-rays), are all factors that make it necessary to choose a higher kV to get better penetrating photons in order to prevent the focus of the Xray tube melting due to high temperature. A higher kV (higher photon energy) will allow use of the desired (and necessary) short exposure time but at the cost of lower object contrast.
In conclusion: To minimize the radiation dose and/or prevent motion unsharpness in images, one may be forced to use higher photon energy than is desirable with regard to good object contrast.
To optimize object contrast -choice of attenuating atom in a contrast medium
From Table 1 it can be observed that at all photon energies (20-150 keV), the atoms of the soft tissues (hydrogen, carbon, nitrogen, oxygen; which are the building stones of the proteins, the fats, the carbohydrates and the water of the soft tissues) all have a lower capacity to attenuate radiation (expressed as barns/atom) than the atoms of the skeleton (for instance, calcium and phosphor). This means that at all used photon energies (20-150 keY), the skeleton attenuates the radiation more than does the soft tissue. Today, iodinated contrast media are used for angiography, urography and contrast-enhanced CT. The thicker the part of the body to be examined with contrast medium, the higher kV one is forced to apply to the X-ray tube. Similarly, restrictions as regards exposure time (X-ray examination of moving objects) may similarly force the choice of high kV setting on the X-ray tube. Then the following question arises: "Is iodine the best radiation attenuator among the nonradioactive atoms of the periodic system for all practical photon energies?"
In Table lone can go from lower to higher photon energies and compare the efficacy of iodine (No. 53) , gadolinium (No. 64), tungsten (No. 74) and bismuth (No. 83) as attenuators of monochromatic X-ray beams at photon energies used in diagnostic radiology! Between 20 and 35 keV the bismuth atom is 6 times and the tungsten atom 4 times more effective than the iodine atom as an attenuator of radiation.
Between 35 and 50 keV iodine is at its best and only bismuth is slightly more effective than iodine (1.1 times).
Between 50 and 70 keV gadolinium is about twice as effective as iodine.
Between 70 and 90 keV tungsten is 3 times and bismuth 1.1 times more effective than iodine.
Between 90 and 150 keV bismuth is 4 times and tungsten is 3 times more effective than iodine.
Conclusion: In the example above bismuth is the only atom that at all photon energies is either a much (3-6 times) or a slightly (1.1 times) better attenuator than iodine. Between 50 and 70 keV gadolinium is the best attenuator, and between 70 and 90 keY it is tungsten, while at all other photon energies bismuth is the strongest attenuator. Let us make the assumption that the chemist could build any high-mass atom into a compact molecule that displays high water solubility and low toxicity. If one had to use one atomic species for all utilized photon energies in diagnostic radiology, then one should select a nonradioactive atomic species with a very high atomic mass, for instance lead or bismuth. If one were allowed to choose different attenuating atoms for different kV-levels, the attenuating atom would be chosen according to its K-edge. Then, one might choose bismuth or its neighbors in the periodic system for photon energies below 50 keV and above 90 keV and perhaps choose gadolinium or its neighbors for photon energies in the range 50 to 70 keY and tungsten or its neighbors for photon energies in the range 70 to 90 keV. This means that the dimensions of the body and/or the need to prevent motion blurring factors (which determine the required photon energy) would determine the choice of which attenuating atom to use in the contrast medium. The advantages of choosing atoms of a higher mass than that of iodine for X-ray contrast media would be seen in terms of higher object contrast and/or a lower radiation dose (39) . In spite of the fact that at all photon energies there are several atoms of high mass that are better attenuators of radiation than iodine (Table I) , con-trast media based on iodine have been the leading media since the 1920s because they have produced fewer adverse biological effects than their noniodinated competitors. Water-soluble contrast media based on cobalt, nickel, copper, zinc, bromine, strontium, cadmium, lanthanum, cesium, gadolinium, ytterbium, lead and bismuth (22, 30, 40) , have been tried but all have produced adverse effects, that in relation to their efficacy, have hitherto been much more serious than those of contemporary iodinated compounds. The domination of the iodine-based iodinated contrast media has been so large that toxicities of different contrast media have been compared in "iodine equivalent doses" and so far there has been no obvious need for applying the concept of "barn equivalent doses".
Before the appearance of the nonionic dimeric media (iotrolan, iodixanol) the water-soluble iodinated contrast media have in most of their clinical applications been used at concentrations that are hypertonic in relation to human plasma and several of their adverse effects have been related to this hypertonicity (osmotoxicity). There has been a need to determine the "ratio" between the "imaging effect" and the "osmotoxic effect" of the media. This "ratio" is "number of iodine atoms" divided by "number of particles of the contrast medium in an ideal solution". The higher the ratio, the lower the degree of osmotoxicity a contrast medium will display.
Nonionic (neutral) monomers with 1 or 2 covalently bound iodine atoms
In the 1920s, BINZ & RATH (7-9) synthesized organic compounds with arsenic, antimony or iodine covalently bound to the heterocyclic compounds pyridine and pyridone in a search for substances for chemotherapy. Some of their iodine compounds had been effective against streptococcus infections in animals and man. The compounds were excreted in the urine and the idea arose to test them for urography in man. SWICK (43) performed clinical trials with those compounds and was first given the nonionic ratio 1 pyridone compound Selectan Neutral (compound I, Fig. 1 ) with 1 covalently bound iodine atom (8) . The ratio between the number of iodine atoms and number of particles in an ideal solution was "one" (1 iodine atom per nondissociating molecule). The compound produced too many adverse reactions. SWIck (8) then received a nonionic ratio 2 pyridone compound with 2 iodine atoms per molecule (compound II, Fig. 1 ). Both that compound and an ionic ratio 1 compound (a sodium salt with 2 iodine atoms per anion -compound III, The ionic compound Uroselectan (compound Iv.', Fig. 1 ), a sodium salt containing 1 iodine atom per anion (a ratio 0.5 compound), with lower animal toxicity and higher water solubility (7-9, 43) than Selectan Neutral was then tried for urography by BINZ (8) and SWICK (43) ; it produced good pyelograms with a low frequency of adverse effects. This started the global use of urography and also the continuous development of water-soluble iodinated contrast media displaying decreasing levels of toxicity, first for urography and angiography and then also for myelography, CT and other applications.
Uroselectan was soon replaced by other ionic pyridone compounds with 2 iodine atoms per anion, such as iodomethamate with a ratio of 0.67 (compound I, Fig. 2 ) and iodopyracet with a ratio of 1 (compound II, Fig. 2 ). In addition, contrast media with 1 or 2 iodine atoms bound to alkanes (iodoalkanesulfonates, compounds ill and IV, Fig. 2) were used for urography. All these substances were generally used for urography in the period 1930 to 1955 and methiodal sodium (compound ill, Fig. 2 ) was used into the 1960s for radiculography of the lumbar region under the protection of spinal anesthesia. These iodopyridones and iodoalkanesulfonates had an i.v. LD so value in mice of the magnitude of2 to 3 g I/kg b.w. In the 1950s they were replaced by the triiodinated aromatic compounds ( Fig. 3 ). 
Ionic monomers with 3 covalently bound iodine atoms

A. Acetrizoate group -1 unsubstituted hydrogen atom on the benzene ring
In acetrizoate (compound I, Fig. 3 ), a benzene compound, 3 of the 6 hydrogen atoms of benzene, are replaced with iodine atoms, 1 hydrogen atom is replaced with 1 salt-forming carboxyl group with sodium as the counter-ion for high water solubility, 1 hydrogen atom is replaced with an acetamido unit and 1 unsubstituted hydrogen atom remains.
It was early recognized in the development of water-soluble iodinated contrast media that many types of iodine-carbon bonds were not sufficiently thermally stable for autoc1aving. The work of BINZ and others (8) represents attempts to produce vinylic carbon-iodine bonds which were chemically more stable than aliphatic carbon-iodine bonds. The most stable carbon-iodine bonds are in an aromatic nucleus. This was first shown by LONG & BURGER (20) and applied by WALLINGFORD and coworkers (46, 47) in the synthesis of acetrizoate, the first triiodinated contrast medium. Salts of these compounds can, in aqueous solution, be autoclaved at l200e for 20 minutes with only negligible de-iodination. WALLINGFORD had also found that small quantities (ppm) of cations (e.g., Fe, Cu) may catalyze the de-iodination that occurs during sterilization. The addition of small quantities of calcium disodium EDTA as a sequestering agent may prevent such catalytic de-iodination.
While in general use, the addition of small quantities of chelating agents has no effect on the biological safety of a contrast medium; some investigators (11) feel that citrate ions or tetrasodium edetate may involve risks in vivo by depleting levels of calcium ions in the heart. (The chelating agent in Visipaque and other modem nonionic contrast media is calcium disodium EDTA, which will not deplete calcium ions in the heart while it is still active as a sequestering agent for Fe and Cu.)
With the arrival of acetrizoate the question arose as to whether it would be possible to create less toxic media and WALLINGFORD (45) wrote in 1959 "The question may be asked: Have today's watersoluble contrast media attained ultimate safety? Probably not, but further progress may be difficult. The acute toxicity (LD so ) of some of these media as measured in animals is more than 109 of medium! kg body weight (equivalent to 5 g IIkg), comparable to that of glucose for i.v. feeding. At these high dosage levels, such factors as concentration and rate of injection are important and make exact determinations or comparisons difficult."
Since the development of acetrizoate it seems to be the tradition that with the development of each "new generation of contrast medium", a discussion starts about whether this latest generation is the ultimate one and whether there is any need for further improvement of the roentgen contrast media.
B. Diatrizoate -all hydrogen atoms on the tri-iodinated benzene ring have been substituted
The presence of 2 acetamido groups gives a certain symmetry to the diatrizoate aniox (compound II, Fig. 3 ). While the i.v. LD so in mice of acetrizoate is around 5 g IIkg, the i.v. LD so of diatrizoate is approximately 5 to 109 IIkg. According to LASSER et al. (18, 19) , the presence of an unsubstituted hydrogen atom on the tri-iodi-nated benzene ring gives a higher degree of binding to proteins than when that hydrogen has been substituted. In diatrizoate the remaining unsubstituted hydrogen (of acetrizoate) has been substituted with another acetamido unit and the accompanying lower binding to plasma proteins might explain the still higher tolerability of diatrizoate than that of acetrizoate.
The high tolerability of diatrizoate resulted in its extensive use. The main drawback with diatrizoate was its relatively low maximal solubility as a pure sodium salt, around 300 mg l/ml, For higher iodine concentrations (400-480 mg IIml), mixtures of sodium and methylglucamine salts were used but this resulted in very high viscosities, most likely explained by the much larger volume of the methylglucamine ion than that of the sodium ion. At high iodine concentrations, solutions of the more toxic substance acetrizoate (as sodium salts) had lower viscosities than those of the less toxic substance diatrizoate. This triggered the development of fully substituted (for assumed low toxicity) tri-iodinated compounds with higher solubility as sodium salts (for assumed low viscosity) than diatrizoate in the hope of combining low toxicity, low viscosity and high iodine concentrations.
C. Nonsymmetrical benzene compoundsno unsubstituted hydrogen atoms on the benzene ring
In the 1960s, iothalamate, metrizoate, iodamide and ioxithalamate (compounds III-VI, Fig. 3 ) were synthesized. They had solubilities as sodium salts of at least 450 mg IIml, and at these high iodine concentrations they had lower viscosities than the more bulky meglumine salts of diatrizoate. It was speculated that at high iodine concentrations the asymmetry of the sodium salts of the iothalamate, metrizoate, iodamide, ioxithalamate (and also the acetrizoate anions) would disturb any tendency to form crystals (a crystal phase) and therefore they tended to remain in the aqueous phase, resulting in higher water solubility than that of the more symmetrical diatrizoate salts. I have used the word "asymmetry" to indicate that beside the iodine atoms there are "3 different" moieties on the benzene nng.
lothalamate and metrizoate as low viscosity sodium salts (most cations were sodium) were fairly widely used, but there was not a complete switch away from the highly viscous meglumine salts of diatrizoate due to 2 factors: 1. the development of catheters with thinner walls; and 2. the finding of lower biological tolerability, in some situations, of the sodium salts than those of meglumine.
1. The laminar flow of a viscous contrast medium through a catheter at a constant pressure gradient along the catheter is inversely proportional to the viscosity of the contrast medium and directly proportional to the 4th power of the inner radius (r) of the catheter. Therefore, a slight decrease in catheter wall thickness made possible by the introduction of improved catheter materials, allowed (at a constant external catheter diameter) an increased inner diam-. eter of the catheter (dr), which gave a flow increase proportional to (r + dr)4/r. While angiography catheters in the 1960s might have had a wall thickness of 0.5 mm, the angiography catheters of the 1990s may tolerate the same injection pressure with a wall thickness of 0.15 mm. This means that with the same outer diameter, the angiography catheters of the 1990s may allow flow rates several times higher (with equal viscosities and injection pressures) than those of the 1960s.
2. In various experiments it was shown that in arteriography, meglumine salts of the tri-iodinated contrast media mentioned above gave fewer signs of damage to the blood-brain barrier or less cardiac response (bradycardia and/or fall in systemic blood pressure) than did the pure sodium salts of the same media (12, 13, 44) .
Addition of calcium and magnesium ions to the contrast media
In the 1960s SALVESEN et al. (36) (37) (38) showed that exchanging some sodium ions in sodium metrizoate with calcium and magnesium ions decreased the frequency of adverse effects on the blood-brain barrier in arteriography. Moreover, acute i.v. tolerance to the medium was increased by 80 to 100% (following rapid injections in different species). Similarly, the frequency of adverse effects on the blood-brain barrier caused by administration of the meglumine salt of the contrast medium could be decreased by the addition of calcium ions (38) . The reduction in amplitude of myocardial contraction, which accompanied perfusion of the isolated rabbit heart with sodium metrizoate or meglumine metrizoate, could also be counteracted by adding calcium ions.
To ameliorate i.v, toxicity maximally, relatively large amounts of calcium and magnesium had to be added so that the relation between concentrations of calcium and sodium ions in the contrast medium (and also the relation between those of magnesium and sodium ions) became several times higher than that in normal plasma. If the relation between calcium and sodium ions in normal plasma was given the number 1 (one), it had to be 2.5 in the contrast medium to achieve a maximum ameliorating effect on i.v, toxicity (LD so in mice). In normal :mman serum the sodium concentration is 140 mM; total calcium concentration is 2.5 mM and free calcium ion concentration is 1.25 mM (ratio "free calcium ions"I"sodium ion"=1.25/140=0.009). In a metrizoate solution equivalent to 440 mg 11m!, the toxic effects of a sodium metrizoate concentration of 1016 mM were ameliorated by adding 26 mM calcium ions and 19 mM magnesium ions as metrizoate (ratio "calcium"l"sodium" =26/1 016= 0.026).
In Visipaque (iodixanol solution) at iodine concentrations of 150/270/320 mg 11m!, the sodium concentrations are 68132/19 mM and the calcium concentrations 0.81/0.63/0.36 mM (the corresponding 3 ratios "calcium"l"sodium" are 0.012/0.0191 0.019. So the ratios "calcium"l"sodium" were highest in the metrizoate solutions (0.026), lower in the iodixanol solutions (0.012-0.019) and lowest in human plasma (0.009).
Adverse effects of the ratio 1.5 media in angiography These compounds, e.g., diatrizoate, iothalamate, and metrizoate, had i.v. LD so values (lethal dose for 50% of animals) in mice of the magnitude 5 to 109 I/kg mouse. At iodine concentrations 300 to 450 mg 11m! they were very hypertonic relative to human serum and had osmolalities in the range 1500 to 2500 mosmlkg water; roughly 5 to 8 times the osmolality of normal human serum.
In angiography, an injected bolus of a contrast medium solution completely replaces the blood in the vessel. Consequently, one should consider all components of the contrast medium having other concentrations in the contrast medium solution than in blood as potential etiologic factors behind the adverse effects the solution causes during angiography. A contrast medium solution has only 1 desired effect -and that is attenuation of radiation. All other effects may be regarded as adverse effects, irrespective of whether they produce clinical signs or not. There is presently little knowledge about the mechanisms of such effects of contrast media, neither on a cellular level nor on a molecular level. The adverse effects of a contrast medium solution may be related to the effects of the solute and/or the effects of the solvent.
Effects ofsolute
Chemotoxicity of contrast medium molecules. This relates to the chemical structure of contrast medium molecules (or contrast medium ions) and depends on the absence or presence of ionizing carboxyl groups, of hydrophilic hydroxyl groups or other hydrophilic groups and of various lipophilic groups. Such lipophilic or hydrophilic parts of the molecules may cause changes in cellular function and/or the release of vasoactive substances via interaction with various proteins in plasma, in cell membranes or inside cells.
Osmotoxicity. This relates to the hypertonicity of various contrast medium solutions causing fluid shifts that result in withdrawal of water out of endothelium cells, blood cells and other cells and contributing to (in combination with chemotoxicity) changes in cellular function and/or the release of various vasoactive substances from the cells. The release of vasoactive substances may then cause various pseudoallergic symptoms.
Effects ofthe solvent
Electrolyte content of the contrast medium solution.
The presence of proper concentrations of sodium ions in solutions of ionic contrast media may minimize the risk of such solutions producing ventricular fibrillation. Proper calcium concentrations and calcium/sodium ratios help minimize the risk of such solutions causing ventricular fibrillation and having adverse effects on cardiac contractility (25, 36, 37, 41, 48) .
Various other factors. The lower the pH of the contrast medium solution, the more vasodilatation and hypotension may be produced following its intravascular injection (16, 23, 27) . The type and concentration of chelating agent present in the contrast medium solution (citrate ions or tetrasodium -EDTA) may influence the concentration of free calcium ions in a mixture of blood and contrast medium and thereby be responsible for the solution having cardiac effects (11) .
Motives for designing contrast media isotonic to human serum
In the 1960s various motives appeared for developing highly concentrated water-soluble angiography contrast media which, ideally, should have been isotonic to serum (or at least less hypertonic than the commonly used ionic ratio 1.5 contrast media of the 1960s) and have low viscosity and low chemotoxicity (1, 2) . The "motives" were: 1. Improved venous filling; 2. Decreased pain in arteriography; 3. Decreased risk of contrast medium-induced arterial hypotension; 4. Decreased incidence of contrast mediumrelated mortality in patients with pulmonary hypertension.
1. Improved venous filling. After a bolus injection of contrast medium into the arteries of an organ there is a lower iodine concentration in the draining veins of that organ than in the arteries. This was thought to be due to both a high level of diffusion of contrast medium from the capillaries into the interstitial fluid and the "osmotic suction of fluid" from the interstitial space into the venous end of the capillaries by the hypertonic contrast medium solution.
It was theorized that I. Large contrast medium molecules such as dimers, trimers, tetramers and oligomers (a "mer" in this context is a tri-iodinated benzene moiety) would show progressively slower diffusion out of the vascular space than the commonly used ionic monomers.
II. Plasma-isotonic (or less hypertonic) contrast medium solutions would draw less fluid from the interstitial space into the vascular space than highly hypertonic media.
III. Media which combined the properties described under I and II (isotonic aqueous solutions of large contrast medium molecules) would, after their injection into the arteries, give a higher iodine concentration in the veins than the ionic monomeric media. A higher iodine concentration in the veins would improve the chances of revealing abnormal venous morphology, for instance due thrombi or tumor infiltration.
2. Decreased pain in arteriography. In arteriography the injection of highly hypertonic solutions (1500-2500 mosm/kg) of ratio 1.5 media often produced pain. It was observed in Japan during the 1930s (31) that an emulsion (which was probably isotonic or moderately hypertonic to plasma) of an iodinated oil causedno pain in arteriography. It was also common knowledge in the 1960s that a moderately hypertonic suspension of thorium dioxide (with an osmolality approximately double that of human plasma) produced no pain in arteriography. It was, therefore, speculated that if isotonic or moderately hypertonic aqueous solutions of contrast media could be synthesized, they too might cause no pain in arteriography.
3. Decreased risk of contrast medium-induced arterial hypotension. It had been observed that intravascular infusions of hypertonic solutions or solutions with low pH produced vasodilatation (16, 27) . As vasodilatation meant an increased risk of hypotension, it was reasoned that the creation of isotonic contrast medium solutions of neutral pH would reduce the acute toxicity of the solutions due to a lower tendency to produce vasodilatation. increased mortality frequency had been observed when hypertonic contrast media were injected into the right atrium or ventricle (26) . Hypertonic solutions were in those days (1950s) considered to increase pulmonary resistance to the flow of red blood cells by producing aggregates of red blood cells which blocked the minor pulmonary vessels (28) . It was theorized that the high contrast medium-related mortality in patients with pulmonary hypertension might be reduced by the creation of contrast medium solutions isotonic to plasma (or at least less hypertonic than the ratio 1.5 media). (It has later been shown (5) that hypertonic solutions of various substances, including contrast media, make the red blood cells rigid by drawing water out of them and that this increases their resistance to flow through the pulmonary vessels.)
Decreased incidence of contrast mediumrelated mortality in patients with
The design of highly hydrophilic nonionic contrast media
The modem angiography ratio 1.5 contrast media of the 1960s (diatrizoate, iothalamate, metrizoate) ( Fig. 3 ) had 3 iodine atoms firmly bound to a benzene ring. In order to provide high water solubility and low toxicity those contrast media had 1 saltforming carboxyl group and 2 other hydrophilic moieties containing a chain of 1 nitrogen and 2 to 3 carbon atoms per benzene ring. All such contrast media were salts of sodium, calcium, magnesium and methylglucamine in different proportions. In aqueous solutions those media dissociated into the above cations and the iodinated anions. Only the anions contained the iodine atoms, which were responsible for the radiologic information (the attenuation of radiation) that was obtained from the use of those media. The cations gave no such information but were responsible for 50% of the osmolality of the contrast solutions.
In view of the above 4 motives for reducing the osmotic effect of the contrast agents, it was apparent that cations which gave no information (not producing major attenuation of radiation) should be eliminated or limited (1) . This could be achieved in 2 ways:
1. The synthesis of nonelectrolytic contrast agents (nonionic media), i.e., media without the ionizing carboxyl groups (without the "structure" COO-Na"), would eliminate the ions. It was sugggested (1, 2) that incorporating a large number of hydroxyl groups in each iodinated molecule might produce the desired high water solubility. Fig. 4 shows some hydrophilic structures suggested for covalent bonding to a benzene ring with 3 iodine atoms to obtain a nondissociating (nonionic) watersoluble contrast medium molecule -a nonionic monomeric contrast medium molecule. This was another approach to the design of nonionic media than that tried by BINZ & RATH (7-9) 40 years earlier (compounds I and II, Fig. 1 ).
2. The synthesis of contrast agents in which both anions and cations contained iodinated benzene rings and thereby gave information.
It was further suggested (1) that the synthesis of small compact polymers (oligomers) of such nonionic contrast media could further reduce the osmolality. It was also suggested that for low viscosity, the ratio between the longest and the shortest axes of these oligomers should be as close to 1 as possible, the goal being the synthesis of a spherical molecule.
The 1st generation nonionic monomersmetrizamide, a ratio 3 medium
All hydroxyl groups at one end of molecule
Metrizamide (Amipaque, Nyegaard & Co, today Nycomed Imaging AS) was the 1st nonionic watersoluble contrast medium for clinical use. Metrizamide (4) is the glucose amide of metrizoic acid (compound I, Fig. 5 ). The metrizamide molecule contains 4 hydroxyl groups positioned at one end of the molecule in the glucosamide moiety (structure A, compound I, Fig. 5 ). When dissolved in water, In the years after the development of metrizamide, research on nonionic contrast media focused on developing substances that could be supplied as ready-for-use autoclaved solutions and with a price that would permit their general use as angiographic, urographic, myelographic and CT enhancement contrast media. Iopamidol and iohexol (compounds II and III, Fig. 5 ) appeared as a result of that work and they have been used extensively for these purposes. They have later been followed by a large number of related compounds (compounds IV-IX, Fig. 5 ). Iohexol and other similar media have a tendency to deteriorate as a result of a cyclizing reaction with release of inorganic iodide that occurs at the high metrizamide forms a molecular (nonionic) solution, and each dissolved molecule contains 3 iodine atoms. For every 3 iodine atoms there is only 1 particle in solution -1 complete, nondissociated metrizamide molecule. The iodine ratio of metrizamide in an ideal solution, therefore, becomes 3.0.
The low acute intravascular toxicity (LD so 15-20 g I1kg mouse) and also the very low subarachnoid toxicity (LD so > 1500 mg I1kg mouse) of metrizamide (33) (34) (35) made it the 1st water-soluble contrast medium with international clinical use in myelography. The subarachnoid LD so in mice of the ionic monomers ( Fig. 3 ) was much lower, 50 to 150 mg II kg mouse. The 10 to 30 times higher tolerance to subarachoid administration of metrizamide was felt to be mostly due to reduced chemotoxicity (the absence of a carboxyl group and presence of many hydroxyl groups); the 2 to 3 times lower osmolality of metrizamide ( Fig. 5 ) than that of the ionic monomers ( Fig. 3 ) could not alone explain its high subarachnoid tolerance.
The use of metrizamide for femoral arteriography in man demonstrated that general use of ratio 3.0 contrast medium virtually almost eliminated the pain normally felt in clinical arteriography (3) . In spite of this advantageous property, metrizamide was used only to a minor extent in clinical arteriography due to 2 disadvantages:
1. It had reduced stability upon autoclaving in aqueous solution which required that metrizamide had to be produced as a lyophilized substance that had to be dissolved in water before it could be used.
2. The lyophilization process resulted in high production costs and the price of the final product was regarded too high for general use in large doses in arteriography. Fig. 5 ). In several countries the ionic monomers have virtually been replaced by the nonionic monomers and there is an extensive literature on their properties in animal experiments and clinical usage. The nonionic monomers represent progress, which may be summarized (without references) in the following way: The acute i.v. tolerability (i.v. LD so ) in various metrizamide. This led to the hypothesis that "nonionic contrast media have lower subarachnoid and i.v. toxicity when the hydroxyl groups or other hydrophilic groups are evenly distributed around the molecule than when placed at 1 end of the molecule". This hypothesis is further supported by the information given in Fig. 6 . Fig. 6 shows the structures of the diatrizoate molecule with I carboxyl group and no hydroxyl group, and an experimental compound with I carboxyl group and 4 hydroxyl groups. Subarachnoid tolerance is much higher with the experimental compound than with diatrizoate, demonstrating that the introduction of hydroxyl groups decreases the subarachnoid neurotoxicity of contrast media.
The experimental contrast medium and metrizamide ( Fig. 6 ) both have 4 hydroxyl groups, but only metrizamide does not contain a carboxyl group. The subarachnoid tolerability of metrizarnide is higher than that of the experimental compound. Thus, eliminating the carboxyl group, markedly reduced contrast medium-related neurotoxicity. Therefore, a contrast medium containing carboxyl groups should not be used for myelography or for enhancement in CT in cases when a damaged blood-brain barrier is suspected, since this would allow contact between nerve cells and intravascularly injected carboxyl group-containing contrast media. Fig. 6 also shows metrizarnide with 4 hydroxyl groups at one end of the molecule as compared to iohexol with 6 hydroxyl groups evenly distributed around the molecule. When animals, premedicated with chlorpromazine, are given a particular dose of contrast medium, they all get seizures after subarachnoid injection of metrizarnide while none does after iohexol (21) . This supports the assumption that the symmetrical distribution of hydroxyl groups around the contrast medium molecule decreases its subarachnoid neurotoxicity. temperatures required for autoclaving (120 DC) (17) . Below pH 5.5 iohexol tolerates autoclaving without deterioration. Contrast media for angiography should not be used in buffered solutions at pH 5.5 because at that low pH they cause a greater decrease in aortic pressure than at pH 7.0 to 7.5 (23) . An elegant solution to the problem was found by RAKLI: Aliphatic amines are known to have pKa values that decrease about 0.025 units/rC upon heating (17) . Iohexol is dissolved in an aqueous buffer of 2amino-2[hydroxymethyl]-1,3-propanediol (also named TRIS) with a pH of 7.3 at 20 DC but at 120 DC its pH will decrease to about pH 5. At this pH and temperature, aqueous solutions of iohexol are stable for hours. After autoclaving and when the iohexol solution is cooled, the pH will return to its initial value. At room temperature and at neutral pH, the stability of iohexol solution is acceptable.
In iohexol and iopamidol the hydroxyl-carrying side-chains are evenly distributed all around the contrast medium molecule (Fig. 5 ). In both iohexol and iopamidol the 3 groups (A, B, C) are carrying hydroxyl-carrying groups. Iohexol and iopamidol have even lower i.v. and subarachnoid toxicity than lotrolan ratio 6.0 lodixanol ratio 6.0 OH OH OH OH species of the different nonionic monomers is approximately 10 times higher than that of the contrast media of the 1930s (Figs. 1 and 2 ) and 2 to 3 times higher than that of the media of the 1950s and 1960s (Fig. 3) . The subarachnoid tolerability values (subarachnoid LD so ) in different species of the various nonionic monomers are 10 to 30 times higher than those of the ionic monomers ( Fig. 3) .
In arteriography the various ionic monomers (Fig. 3 ) at concentrations used (300-450 mg l/ml) have an osmolality 5 to 8 times higher than that of human plasma while the nonionic monomers ( Fig.  5 ), when they are used for arteriography (iodine concentration 300-350 mg l/ml), have osmolalities 2 to 3 times that of human plasma. The higher level of patient comfort (less contrast medium-caused pain in arteriography) experienced with nonionic monomers (ratio 3) than with ionic monomers (ratio 1.5) is ascribed to reduced hyperosmolality.
The higher i.v. and subarachnoid tolerability values of the nonionic media ( Fig. 5 ) than those of the ionic monomers ( Fig. 3 ) are ascribed to reduced hyperosmolality, absence of carboxyl groups and presence of a large number of hydroxyl groups.
By adding small amounts of sodium and calcium ions to solutions of the nonionic monomers ( Fig. 5) , cardiac tolerability can be further improved (decreased effects on cardiac contractility, decreased risk of ventricular fibrillation).
Nonionic dimers -the plasma-isotonic ratio 6 media
In the 1980s and 1990s there has been ongoing development of nonionic dimers and of solutions of nonionic dimers that are enriched with plasma electrolytes. The rationale for this development is the possibility of obtaining solutions of iodinated contrast media, which are isotonic to plasma in concentrations useful for arteriography (approximately 300 mg Vml).
The nonionic dimers are based on principles gained from the design of iodinated contrast medium as regards low toxicity. They contain:
1. Completely substituted tri-iodinated benzene rings (principle of LASSER);
2. An absence of carboxyl groups, particularly for low neurotoxicity;
3. The presence of hydroxyl groups evenly distributed around the molecule.
In addition to the above, 2 further "steps forward" have been achieved:
1. Isotonicity to plasma (all previous media have been hyperosmolal in relation to plasma at iodine concentrations useful for arteriography).
2. While maintaining isotonicity, there is some room for adding small amounts of ions, for instance sodium and calcium ions.
The 1st nonionic water-soluble dimers in clinical use were iotrolan and iodixanol ( Fig. 7) , both of which contain 6 iodine atoms per molecule and, therefore, are ratio 6 media. Pure aqueous solutions of these nonionic dimers are hypotonic to plasma at iodine concentrations useful for angiography and thus these media may be enriched with plasma electrolytes and still maintain isotonicity with plasma.
Iodixanol, which contains 6 iodine atoms per molecule, no carboxyl groups and has 9 hydroxyl groups evenly distributed around the molecule, is expected to have an acute i.v. tolerability in animals that is equal to (or even better than?) that of the nonionic monomers shown Fig. 5 . It turned out (32) that the acute i.v. tolerability of iodixanol was in 1 species (rat) even higher than that of iohexol, iopentol and ioparnidol. In this set of experiments, the i.v. LD so in rats was approximately 20 g I1kg rat for iodixanol while it was around 12 g I1kg rat for iohexol, iopentol and ioparnidol.
Predictions about Visipaque (an aqueous iodixanol solution enriched with sodium and calcium ions)
The development from tri-iodinated ionic monomers to nonionic monomers and further to nonionic dimers has meant increased viscosity (Table 2) , which is confirmed by the fact that the highest con- centrations for arteriography supplied by the contrast medium producers have decreased. For the ionic monomers the concentrations were 440 to 480 mg IIml, for nonionic monomers 350 to 370 mg II mI, and for nonionic dimers 300 to 320 mg llmI. The disadvantage of high viscosity of contrast medium solutions has to some extent been counteracted by the development of angiography catheters with thinner walls, and it should be remembered that the laminar flow of contrast medium through a catheter at a certain injection pressure is proportional to the 4th power of the inner radius of the catheter. A nonionic highly hydrophilic isotonic dimer enriched with sodium and calcium ions would be expected to show a number of advantages based on the data and concepts presented in this review:
Improved venous filling in arteriography. Among the presently used contrast media for arteriography (ionic monomers, ionic dimers, nonionic monomers, and nonionic dimers), the nonionic dimers have the largest molecular mass and molecular volume and they are the only media which in aqueous solutions are isotonic to plasma. Therefore, among the media compared, they are expected to produce the highest iodine concentration in the veins following i.a. injection. Consequently, at i.a. injection, better depiction of venous morphology and pathology is expected than with the other water-soluble iodinated contrast media in clinical use.
Isotonic solutions of nonionic dimers are expected to cause little or no pain in arteriography; due to their plasma isotonicity and low chemotoxicity (absence of carboxyl groups, presence of many hydroxyl groups) they are assumed to be less irritant to the vessel wall than solutions of ionic monomers, ionic dimers and nonionic monomers.
Nonionic dimers are expected to show low neurotoxicity following subarachnoid injection due to the absence of carboxyl groups, presence of hydroxyl groups evenly distributed around the molecule and isotonicity to cerebrospinal fluid.
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Visipaque solutions are expected to have only small effects on cardiac contractile force following intracoronary injection as a result of low chemotoxicity (as above) and the presence of small amounts of sodium and calcium ions (balanced electrolytes).
Visipaque solutions are expected to have low fibrillatory propensities in coronary arteriography due to low chemotoxicity, isotonicity and the presence of sodium and calcium ions in concentrations determined from tests in isolated hearts to find the concentrations that give minimal effects on cardiac contractile force and have minimal fibrillatory propensity (see Cardiovascular Safety, Acta Radiol. 36 (1995) , Suppl. 399, pp. 100-169).
Visipaque solutions are expected to have minimal effects on red blood cells when mixed with blood due to their isotonicity, which should counteract major fluid shifts over the membranes of the red blood cells.
Solutions of Visipaque are expected to have few, if any, effects on plasma proteins because the solutions are isotonic, highly hydrophilic, display low protein binding, and the presence of electrolytes should counteract the aggregation of proteins that sometimes occurs in fluids devoid of electrolytes.
Renal safety may be difficult to predict because different factors point in 2 directions. The renal toxicity of the iodixanol molecule should be low, pointing towards high renal safety. On the other hand, the low osmolality of iodixanol solutions may give rise to low osmotic diuresis with an accompanying high iodixanol concentration in tubular urine and a high viscosity of primary urine, both of which are effects that might point in the opposite direction (see Renal Safety, Acta Radiol. 36 (1995) , Suppl. 399, pp. 191-218, where which of the predictions to be correct are discussed).
Overall, the combination of the above assumed advantages of nonionic dimers might mean that relatively few adverse effects will be seen with these dimers in clinical use.
